Efficacy and Safety Study of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.
Also called NCT05110898
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 400 participants
- Sponsor
- Brainfarma Industria Química e Farmacêutica S/A
- Registry
-
NCT05110898
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT05110898. Randomized; single masking; primary purpose treatment. Start 2022-08-01 (anticipated); primary completion 2023-08-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension.
- Acronym
- OLINDA
- Condition
- Hypertension
- Condition
- Hypertension,Essential
- Intervention (Drug)
- fixed-dose of olmesartan 20mg/40 mg + indapamide 1,5 mg
- Intervention (Drug)
- Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg)
- Lead sponsor
- Brainfarma Industria Química e Farmacêutica S/A
Record details
- Record id
cardio:ct-nct05110898- Content hash
4a7f91c93e244f2d8fcd5dc20890ee7190156e806a17b5293e7022664436942c